The trial is a phase II study of daily Tarceva combined with definitive radiotherapy in inoperable locally advanced non small cell lung cancer (stage IIB-IIIB). The objective of the phase II trial is to examine Tarceva concomitant with curatively intended irradiation 66 Gy (2 Gy x 33 F, 5 F per week).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
Tarceva 150 mg/day
66 Gy/33 F/5 F per week for 5 weeks
Department of Oncology, Aarhus University Hospital
Aarhus, Denmark
Department of Oncology, Rigshospitalet
Copenhagen, Denmark
Department of Oncology, Copenhagen University Hospital at Herlev
Herlev, Denmark
Department of Oncology, Naestved Hospital
Næstved, Denmark
Progression Free Survival
Progression free survival from registration according to RECIST 1.1
Time frame: 3 years
Toxicity
Time frame: 3 years
Local Tumor Control by CT-scan
Time frame: May 2012
Overall Response Rate (CR + PR)
Time frame: May 2012
Local Tumor Control at 9 Months Evaluated by PET-CT
Time frame: May 2012
Overall Survival
Time frame: May 2012
Disease Free Survival
Time frame: May 2012
Late Toxicity
Time frame: May 2012
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Laboratory of Radiation Physics
Odense, Denmark
Odense University Hospital
Odense, Denmark
Department of Oncology, Vejle Hospital
Vejle, Denmark